As various mechanisms of switch towards elevated levels of MCL-1L were shown in cancer cells [38, 40, 52], targeting the alternative splicing machinery to promote MCL-1S expression can be exploited to improve the efficacy of anti-cancer drugs (Fig. 3). Here, MCL1 is linked to cancer.